Prochieve 8% gel
Prochieve (progesterone gel) is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system, which is contained in single use, one piece polyethylene vaginal applicators. The carrier vehicle is an oil in water emulsion containing the water swellable, but insoluble polymer, polycarbophil. The progesterone is partially soluble in both the oil and water phase of the vehicle, with the majority of the progesterone existing as a suspension. Physically, Prochieve has the appearance of a soft, white to off-white gel.
The active ingredient, progesterone, is present in either a 4% or an 8% concentration (w/w). The chemical name for progesterone is pregn-4-ene-3,20-dione. It has an empirical formula of C 21 H 30 O 2 and a molecular weight of 314.5. The structural formula is:
Progesterone exists in two polymorphic forms. Form 1, which is the form used in Prochieve, exists as white orthorhombic prisms with a melting point of 127-131°C.
Each applicator delivers 1.125 grams of Prochieve gel containing either 45 mg (4% gel) or 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, sodium hydroxide and purified water.
Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is essential for the development of decidual tissue, and the effect of progesterone on the differentiation of glandular epithelia and stroma has been extensively studied. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain the pregnancy. Normal or near-normal endometrial responses to oral estradiol and intramuscular progesterone have been noted in functionally agonadal women through the sixth decade of life. Progesterone administration decreases the circulatory levels of gonadotropins.
Due to the sustained release properties of Prochieve, progesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours, and an elimination half-life of 5-20 minutes. Therefore, the pharmacokinetics of Prochieve are rate-limited by absorption rather than by elimination.
The bioavailability of progesterone in Prochieve was determined relative to progesterone administered intramuscularly. In a single dose crossover study, 20 healthy, estrogenized postmenopausal women received 45 mg or 90 mg progesterone vaginally in Prochieve 4% or Prochieve 8%, or 45 mg or 90 mg progesterone intramuscularly. The pharmacokinetic parameters (mean ± standard deviation) are shown in Table 1.
The multiple dose pharmacokinetics of Prochieve 4% and Prochieve 8% administered every other day and Prochieve 8% administered daily or twice daily for 12 days were studied in 10 healthy, estrogenized postmenopausal women in two separate studies. Steady state was achieved within the first 24 hours after initiation of treatment. The pharmacokinetic parameters (mean ± standard deviation) after the last administration of Prochieve 4% or 8% derived from these studies are shown in Table 2.
Progesterone is extensively bound to serum proteins (~96-99%), primarily to serum albumin and corticosteroid binding globulin.
The major urinary metabolite of oral progesterone is 5(beta)-pregnan-3(alpha), 20(alpha)-diol glucuronide which is present in plasma in the conjugated form only. Plasma metabolites also include 5(beta)-pregnan-3(alpha)-ol-20-one (5(beta)-pregnanolone) and 5(alpha)-pregnan-3(alpha)-ol-20-one (5(alpha)-pregnanolone).
Progesterone undergoes both biliary and renal elimination. Following an injection of labeled progesterone, 50-60% of the excretion of progesterone metabolites occurs via the kidney; approximately 10% occurs via the bile and feces, the second major excretory pathway. Overall recovery of labeled material accounts for 70% of an administered dose, with the remainder of the dose not characterized with respect to elimination. Only a small portion of unchanged progesterone is excreted in the bile.
Assisted Reproductive Technology
In a single-center, open-label study (COL1620-007US), 99 women (aged 28-47 years) with either partial (n=84) or premature ovarian failure (n=15) who were candidates to receive a donor oocyte transfer as an Assisted Reproductive Technology ("ART") procedure were randomized to receive either Prochieve 8% twice daily (n=68) or intramuscular progesterone 100 mg daily (n=31). The study was divided into three phases (Pilot, Donor Egg and Treatment). The first phase of the study consisted of a test Pilot Cycle to ensure that the administration of transdermal estradiol and progesterone would adequately prime the endometrium to receive the donor egg. The second phase was the Donor Egg Cycle during which a fertilized oocyte was implanted. Prochieve 8% was administered beginning the evening of Day 14 of the Pilot and Donor Egg cycles. Subjects with partial ovarian function also underwent a Pre-Pilot Cycle and a Pre-Donor Egg Cycle during which time they were administered only leuprolide acetate to suppress remaining ovarian function. The Pre-Pilot Cycle, Pilot Cycle, Pre-Donor Egg Cycle, and Donor Egg Cycle each lasted approximately 34 days. The third phase of the study consisted of a 10-week treatment period to maintain a pregnancy until placental autonomy was achieved.
Sixty-one women received Prochieve 8% as part of the Pilot Cycle to determine their endometrial response. Of the 55 evaluable endometrial biopsies in the Prochieve 8% group performed on Day 25-27, all were histologically "in-phase", consistent with luteal phase biopsy specimens of menstruating women at comparable time intervals. Fifty-four women who received Prochieve 8% and had a histologically "in-phase" biopsy received a donor oocyte transfer. Among these 54 Prochieve-treated women, clinical pregnancies (assessed about week 10 after transfer by clinical examination, ultrasound and/or (beta)-hCG levels) occurred in 26 women (48%). In these 26 women, 17 women (31%) delivered a total of 25 newborns, seven women (13%) had spontaneous abortions and two women (4%) had elective abortions.
In a second study (COL1620-F01), Prochieve 8% was used in luteal phase support of women with tubal or idiopathic infertility due to endometriosis and normal ovulatory cycles, undergoing in vitro fertilization ("IVF") procedures. All women received a GnRH analog to suppress endogenous progesterone, human menopausal gonadotropins, and human chorionic gonadotropin. In this multi-center, open-label study, 139 women (aged 22-38 years) received Prochieve 8% once daily beginning within 24 hours of embryo transfer and continuing through Day 30 post-transfer. Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. Thirty-two women (23%) delivered newborns and four women (3%) had spontaneous abortions. (See PRECAUTIONS , subsection Pregnancy )
In three parallel, open-label studies (COL1620-004US, COL1620-005US, COL1620-009US), 127 women (aged 18-44) with hypothalamic amenorrhea or premature ovarian failure were randomized to receive either Prochieve 4% (n=62) or Prochieve 8% (n=65). All women were treated with either conjugated estrogens 0.625 mg daily (n=100) or transdermal estradiol (delivering 50 mcg/day) twice weekly (n=27).
Estrogen therapy was continuous for the entire three 28-day cycle studies. At Day 15 of the second cycle (six weeks after initiating estrogen replacement), women who demonstrated adequate response to estrogen therapy (by ultrasound) and who continued to be amenorrheic received Prochieve every other day for six doses (Day 15 through Day 25 of the cycle).
In cycle 2, Prochieve 4% induced bleeding in 79% of women and Prochieve 8% induced bleeding in 77% of women. In the third cycle, estrogen was continued and Prochieve was administered every other day beginning on Day 15 for six doses. On Day 24 an endometrial biopsy was performed. In 53 women who received Prochieve 4%, biopsy results were as follows: 7% proliferative, 40% late secretory, 19% mid secretory, 13% early secretory, 7% atrophic, 6% menstrual endometrium, 6% inactive endometrium and 2% negative endometrium. In 54 women who received Prochieve 8%, biopsy results were as follows: 44% late secretory, 19% mid secretory, 11% early secretory, 19% atrophic, 5% menstrual endometrium and 2% "oral contraceptive like" endometrium.
Indications and Usage
Assisted Reproductive Technology
Prochieve 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency.
Prochieve 4% is indicated for the treatment of secondary amenorrhea. Prochieve 8% is indicated for use in women who have failed to respond to treatment with Prochieve 4%.
Prochieve should not be used in individuals with any of the following conditions:
- Known sensitivity to Prochieve (progesterone or any of the other ingredients)
- Undiagnosed vaginal bleeding
- Liver dysfunction or disease
- Known or suspected malignancy of the breast or genital organs
- Missed abortion
- Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders
The physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). Should any of these occur or be suspected, the drug should be discontinued immediately.
Progesterone and progestins have been used to prevent miscarriage in women with a history of recurrent spontaneous pregnancy losses. No adequate evidence is available to show that they are effective for this purpose.
- The pretreatment physical examination should include special reference to breast and pelvic organs, as well as Papanicolaou smear.
- In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional causes should be considered. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures should be undertaken.
- Because progestogens may cause some degree of fluid retention, conditions which might be influenced by this factor (e.g., epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.
- The pathologist should be advised of progesterone therapy when relevant specimens are submitted.
- Patients who have a history of psychic depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
- A decrease in glucose tolerance has been observed in a small percentage of patients on estrogen-progestin combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progestin therapy.
Information for Patients
The product should not be used concurrently with other local intravaginal therapy. If other local intravaginal therapy is to be used concurrently, there should be at least a 6-hour period before or after Prochieve administration. Small, white globules may appear as a vaginal discharge possibly due to gel accumulation, even several days after usage.
No drug interactions have been assessed with Prochieve.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Nonclinical toxicity studies to determine the potential of Prochieve to cause carcinogenicity or mutagenicity have not been performed. The effect of Prochieve on fertility has not been evaluated in animals.
Pregnancy (See CLINICAL PHARMACOLOGY , subsection Clinical Studies )
Prochieve 8% has been used to support embryo implantation and maintain pregnancies through its use as part of ART treatment regimens in two clinical studies (studies COL1620-007US and COL1620-F01). In the first study (COL1620-007US), 54 Prochieve-treated women had donor oocyte transfer procedures, and clinical pregnancies occurred in 26 women (48%). The outcomes of these 26 pregnancies were as follows: one woman had an elective termination of pregnancy at 19 weeks due to congenital malformations (omphalocele) associated with a chromosomal abnormality; one woman pregnant with triplets had an elective termination of her pregnancy; seven women had spontaneous abortions; and 17 women delivered 25 apparently normal newborns.
In the second study (COL1620-F01), Prochieve 8% was used in the luteal phase support of women undergoing in vitro fertilization ("IVF") procedures. In this multi-center, open-label study, 139 women received Prochieve 8% once daily beginning within 24 hours of embryo transfer and continuing through Day 30 post-transfer.
Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. Thirty-two women (23%) delivered newborns and four women (3%) had spontaneous abortions. Of the 47 newborns delivered, one had a teratoma associated with a cleft palate; one had respiratory distress syndrome; 44 were apparently normal and one was lost to follow-up.
The safety and effectiveness in geriatric patients (over age 65) have not been established.
Safety and effectiveness in pediatric patients have not been established.
Detectable amounts of progestins have been identified in the milk of mothers receiving them. The effect of this on the nursing infant has not been determined.
Assisted Reproductive Technology
In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure receiving Prochieve 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3.
In a second clinical study of 139 women using Prochieve 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in >/=5% of the women are shown in Table 4.
In three studies, 127 women with secondary amenorrhea received estrogen replacement therapy and Prochieve 4% or 8% every other day for six doses. Treatment emergent adverse events during estrogen and Prochieve treatment that occurred in 5% or more of women are shown in Table 5.
Additional adverse events reported in women at a frequency <5% in Prochieve ART and secondary amenorrhea studies and not listed in the tables above include:
Autonomic Nervous System —mouth dry, sweating increased
Body as a Whole —abnormal crying, allergic reaction, allergy, appetite decreased, asthenia, edema, face edema, fever, hot flushes, influenzalike symptoms, water retention, xerophthalmia
Cardiovascular, General —syncope
Central and Peripheral Nervous System —migraine, tremor
Gastro-Intestinal —dyspepsia, eructation, flatulence, gastritis, toothache
Metabolic and Nutritional —thirst
Musculo-Skeletal System —cramps legs, leg pain, skeletal pain
Neoplasm —benign cyst
Platelet, Bleeding & Clotting —purpura
Psychiatric —aggressive reactions, forgetfulness, insomnia
Red Blood Cell —anemia
Reproductive, Female —dysmenorrhea, premenstrual tension, vaginal dryness
Resistance Mechanism —infection, pharyngitis, sinusitis, urinary tract infection
Respiratory System —asthma, dyspnea, hyperventilation, rhinitis
Skin and Appendages —acne, pruritis, rash, seborrhea, skin discoloration, skin disorder, urticaria
Urinary System —cystitis, dysuria, micturition frequency
Vision Disorders —conjunctivitis
There have been no reports of overdosage with Prochieve. In the case of overdosage, however, discontinue Prochieve, treat the patient symptomatically, and institute supportive measures.
As with all prescription drugs, this medicine should be kept out of the reach of children.
Dosage and Administration
Assisted Reproductive Technology
Prochieve 8% is administered vaginally at a dose of 90 mg once daily in women who require progesterone supplementation. Prochieve 8% is administered vaginally at a dose of 90 mg twice daily in women with partial or complete ovarian failure who require progesterone replacement. If pregnancy occurs, treatment may be continued until placental autonomy is achieved, up to 10-12 weeks.
Prochieve 4% is administered vaginally every other day up to a total of six doses. For women who fail to respond, a trial of Prochieve 8% every other day up to a total of six doses may be instituted.
It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.
SEE Prochieve PATIENT INFORMATION SHEET - HOW TO USE Prochieve. Note: The PATIENT INFORMATION SHEET contains special instructions for using the applicator at altitudes above 2500 feet in order to avoid a partial release of Prochieve before vaginal insertion.
Prochieve is available in the following strengths:
4% gel (45 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel.
NDC-55056-0406-1 - 6 Single-use prefilled applicators.
8% gel (90 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel.
NDC-55056-0806-1 - 6 Single-use prefilled applicators.
NDC-55056-0818-1 - 18 Single-use prefilled applicators
Each applicator is wrapped and sealed in a foil overwrap.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
U.S. Patent Numbers 4,615,697 and 5,543,150.
Manufactured for: Columbia Laboratories, Inc. Livingston, NJ 07039
Manufactured by: Fleet Laboratories Ltd., Watford, United Kingdom
40905010002 Revised February 2004
PRODUCT PHOTO(S):NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.
The product samples shown here have been supplied by the manufacturer. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug's identity should be verified by chemical analysis.